India Pharma Outlook Team | Monday, 06 October 2025
Eli Lilly and Company has revealed a substantial investment in India of up to $1 billion over the next few years to build new contract manufacturing facilities and a new advanced manufacturing and quality hub in Hyderabad.
The US pharma company said the bet will further strengthen its global supply capabilities and tap into India's deep talent in engineering, chemistry, and life sciences.
The new facility in Hyderabad will be a hub for technical expertise and quality oversight throughout Lilly's contract manufacturing network in India. The company has already begun hiring engineers, chemists, analytical scientists, quality professionals, and managers for the future operations.
Also Read: Oral GLP-1 Drugs: Expanding Patient Access in Obesity and Diabetes Care
Patrik Jonsson, Executive Vice President and President of Lilly International, commented that the investment highlights the company's confidence in India-playing a global role in manufacturing and innovation. A. Revanth Reddy, Chief Minister of Telangana, further embraced the announcement, stating that it is a powerful validation of Hyderabad’s emergence as a leading healthcare innovation hub. With the expansion, Eli Lilly further cements its breadth of capabilities into India's growing life sciences ecosystem.
Telangana’s IT & industries minister D Sridhar Babu said Lilly’s expansion in Hyderabad was a testament to the state’s dynamic industrial landscape and growing influence in advanced healthcare manufacturing.
This investment is part of Lilly's wider strategy for global expansion. Since 2020, Lilly has invested more than $55 billion to build, expand, and acquire its plants in the US and elsewhere. This investment supports the development of new medicines targeting diabetes, obesity, Alzheimer's, cancer, and autoimmune diseases.
